Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

NCT03091465 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT03091465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03091465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Observational
Overall status
Completed
Start date
December 20, 2016
Completion date
April 17, 2017
Enrollment
530 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma